None of the four clinical trials of CETP inhibitors published by May 2018 have reported associations with breast cancer occurrence, although the proportion of women (19.2% across trials) and the short follow-up of up to 4.1 years pose limitations on the detection of potential cancer-related effects. The gene discussed is CETP; the disease is cancer.